<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920618</url>
  </required_header>
  <id_info>
    <org_study_id>PL6</org_study_id>
    <nct_id>NCT03920618</nct_id>
  </id_info>
  <brief_title>Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF</brief_title>
  <acronym>HBV</acronym>
  <official_title>Study on Three Types of Nucleotide/Nucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside
      analogues in treatment of HBV-related acute-on-chronic liver failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis b virus (HBV) related acute-on-chronic liver failure (ACLF) is a serious condition
      with high mortality rate in China. Nucleotide/nucleoside analogues are used for anti-virus
      treatment in these patients. Entecavir, Tenofovir Disoproxil Fumarate and Tenofovir
      Alafenamide are first line drug in China. But there still lacks of data of Tenofovir
      Alafenamide in treatment of HBV related ACLF. This study is to investigate the clinical
      efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV related ACLF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate in the follow-up</measure>
    <time_frame>144 week</time_frame>
    <description>Whether patients will survive after treatment is observed in the follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Model for end-stage liver disease (MELD) score is recorded after treatment</measure>
    <time_frame>0 week, 4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week</time_frame>
    <description>The calculation of model for end-stage liver disease (MELD) score is: R=0.378ln[serum total bilirubin (mg/dl)]+1.12ln(prothrombin time international normalized ratio)+0.95ln[serum creatinin(mg/dl)]+0.64. The higher the MELD score, the higher the mortality rate. MELD score is recorded after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with undetectable hepatitis b virus DNA after treatment</measure>
    <time_frame>4 week, 8 week, 12 week, 24 week, 48 week, 72 week,144 week</time_frame>
    <description>Hepatitis b virus DNA would be tested to know the ratio of patients with undetectable hepatitis b virus DNA at 7 time points after treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>ETV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.</description>
    <arm_group_label>ETV group</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.</description>
    <arm_group_label>TDF group</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.</description>
    <arm_group_label>TAF group</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive hepatitis b surface antigen or hepatitis b virus DNA &gt; 0.5 year;

          2. Age from 18 to 55 years old;

          3. Serum total bilirubin level &gt; 10 times upper limit of normal;

          4. Prothrombin time activity &lt; 40% or prothrombin time international ratio &gt; 1.5ï¼›

          5. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

        Exclusion Criteria:

          1. Other active liver diseases;

          2. Hepatocellular carcinoma or other malignancy;

          3. Pregnancy or lactation;

          4. Human immunodeficiency virus infection or congenital immune deficiency diseases;

          5. Severe diabetes, autoimmune diseases;

          6. Other important organ dysfunctions;

          7. Using glucocorticoid;

          8. Patients can not follow-up;

          9. Investigator considering inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiong Xu, Doctor</last_name>
    <phone>+8613760783281</phone>
    <email>xwx1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>hepatitis b virus</keyword>
  <keyword>acute-on-chronic liver failure</keyword>
  <keyword>nucleotide</keyword>
  <keyword>nucleoside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

